SA
VRTX icon

Strategic Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$403K Sell
812
-7,482
-90% -$3.32M 0.09% 126
2026
Q1 		$3.7M Sell
8,294
-481
-5% -$224K 0.62% 42
2025
Q4 		$3.98M Sell
8,775
-79
-0.9% -$34.1K 0.62% 38
2025
Q3 		$3.47M Buy
8,854
+4,272
+93% +$1.79M 0.56% 39
2025
Q2 		$2.04M Buy
4,582
+2
+0% +$922 0.4% 61
2025
Q1 		$2.22M Buy
4,580
+94
+2% +$43.8K 0.43% 47
2024
Q4 		$1.81M Buy
4,486
+25
+0.6% +$11.6K 0.33% 62
2024
Q3 		$2.07M Hold
4,461
– – 0.39% 61
2024
Q2 		$2.09M Buy
4,461
+3,905
+702% +$1.69M 0.41% 60
2024
Q1 		$232K Buy
556
+31
+6% +$13.1K 0.05% 185
2023
Q4 		$214K Buy
+525
New +$194K 0.04% 190

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Strategic Advisors's VRTX Position: Q2 2026 in Review

Strategic Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 90% in Q2 2026, selling an estimated $3.32M and leaving 812 shares worth $403K. The position accounts for 0.09% of the portfolio, ranked #126.

Strategic Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.98M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Strategic Advisors held 812 shares of Vertex Pharmaceuticals worth $403K as of Q2 2026.
  • Strategic Advisors sold 7,482 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.32M.
  • Vertex Pharmaceuticals made up 0.09% of Strategic Advisors's portfolio in Q2 2026, its #126 holding.
  • Strategic Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Strategic Advisors's Vertex Pharmaceuticals position peaked at $3.98M in Q4 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Strategic Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.